Risk based and response adapted radiation therapy for children and adolescents with newly diagnosed advanced stage Hodgkin lymphoma treated with ABVD chemotherapy: a report from the Indian pediatric oncology group study InPOG-HL-15-01

• Published in: Leukemia & lymphoma 2022-05, Vol.63 (5), p.1111-1118
• Main Authors: Jain, Sandeep, Bakhshi, Sameer, Seth, Rachna, Verma, Nishant, Singh, Manisha, Mahajan, Amita, Radhakrishnan, Venkatraman, Mandal, Piali, Arora, Ramandeep, Dinand, Veronique, Kalra, Manas, Sharma, Anurag, Taluja, Ankit, Thulkar, Sanjay, Biswas, Ahitagni, Chandra, Jagdish
• Format: Article
• Language: English
• Subjects: ABVD; advanced stage; chemotherapy; Hodgkin lymphoma; radiotherapy
• ISSN: 1042-8194; 1029-2403
• DOI: 10.1080/10428194.2021.2012659

This multi-centric prospective study (InPOG-HL-15-01) assessed epidemiological, clinical and outcome data of advanced stage Hodgkin Lymphoma (IIB, III and IV) in children and adolescents (N = 262). Chemotherapy regimen was ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) and radiotherapy (RT) was restricted to patients with bulky disease at diagnosis or with suboptimal response at early response assessment (ERA). ERA revealed complete response in 175 (68.1%), partial response in 77 (29.9%), stable disease in 2 (0.8%), and progressive disease in 3 (1.2%) patients. RT was administered to 111 (97 bulky disease, 14 suboptimal response) patients. Five-year event free (EFS) and overall survival for the whole cohort was 81.1% and 90.8% respectively. On multivariate analysis, the only statistically significant predictor of EFS was use of RT (89% versus 74.2%; p-value